EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, LTRN: Lantern Pharma Inc

26 Nov 25 15:59
LAST:

3.850

CHANGE:
 0.03		OPEN:
3.830		HIGH:
3.930		ASK:
0.000		VOLUME:
64.1K
CHG(%):
0.78		PREV:
3.830		LOW:
3.665		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Nov 253.8303.9303.6653.85064.1K
25 Nov 253.4603.8403.4303.830108.3K
24 Nov 253.2903.4903.2203.370164.8K
21 Nov 253.0003.2322.8603.02085.2K
20 Nov 253.2303.4193.0003.00067.9K
19 Nov 253.2103.4103.1593.27058.6K
18 Nov 253.2803.3873.1583.21040.5K
17 Nov 253.4403.5503.2003.36058.4K
14 Nov 253.3703.5303.3603.38034.2K
13 Nov 253.5803.7003.4003.46059.0K

PROFILE

Name:Lantern Pharma Inc
About:Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Sector:Healthcare
Industry:Biotechnology
Address:1920 McKinney Avenue, Dallas, TX, United States, 75201
Website:https://www.lanternpharma.com
CUSIP:51654W101
CIK:0001763950
ISIN:US51654W1018
FIGI:BBG00GM6LK17

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:3.4013.1%
MA10:3.3714.2%
MA20:3.5010.0%
MA50:3.932.1%
MA100:4.096.2%
MA200:3.811.0%
STO9:86.02 
STO14:86.02 
RSI14:62.79 
WPR14:-3.61 
MTM14:0.38
ROC14:0.11 
ATR:0.31 
Week High:3.932.1%
Week Low:2.8634.6%
Month High:4.2811.2%
Month Low:2.861.0%
Year High:6.1258.9%
Year Low:2.5551.0%
Volatility:21.35